Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models
- PMID: 27161639
- PMCID: PMC4958192
- DOI: 10.1128/AAC.02708-15
Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models
Abstract
Immune response stimulation to prevent infection progression may be an adjuvant to antimicrobial treatment. Lysophosphatidylcholine (LPC) is an immunomodulator involved in immune cell recruitment and activation. In this study, we aimed to evaluate the efficacy of LPC in combination with colistin, tigecycline, or imipenem in experimental murine models of peritoneal sepsis and pneumonia. We used Acinetobacter baumannii strain Ab9, which is susceptible to colistin, tigecycline, and imipenem, and multidrug-resistant strain Ab186, which is susceptible to colistin and resistant to tigecycline and imipenem. Pharmacokinetic and pharmacodynamic parameters for colistin, tigecycline, and imipenem and the 100% minimal lethal dose (MLD100) were determined for both strains. The therapeutic efficacies of LPC, colistin (60 mg/kg of body weight/day), tigecycline (10 mg/kg/day), and imipenem (180 mg/kg/day), alone or in combination, were assessed against Ab9 and Ab186 at the MLD100 in murine peritoneal sepsis and pneumonia models. The levels of pro- and anti-inflammatory cytokines, i.e., tumor necrosis factor alpha (TNF-α) and interleukin-10 (IL-10), were determined by enzyme-linked immunosorbent assay (ELISA) for the same experimental models after inoculating mice with the MLD of both strains. LPC in combination with colistin, tigecycline, or imipenem markedly enhanced the bacterial clearance of Ab9 and Ab186 from the spleen and lungs and reduced bacteremia and mouse mortality rates (P < 0.05) compared with those for colistin, tigecycline, and imipenem monotherapies. Moreover, at 4 h post-bacterial infection, Ab9 induced higher TNF-α and lower IL-10 levels than those with Ab186 (4 μg/ml versus 3 μg/ml [P < 0.05] and 2 μg/ml versus 3.4 μg/ml [P < 0.05], respectively). LPC treatment combined with colistin, tigecycline, or imipenem modestly reduced the severity of infection by A. baumannii strains with different resistance phenotypes compared to LPC monotherapy in both experimental models.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Figures

Similar articles
-
Efficacy of Lysophosphatidylcholine as Direct Treatment in Combination with Colistin against Acinetobacter baumannii in Murine Severe Infections Models.Antibiotics (Basel). 2021 Feb 17;10(2):194. doi: 10.3390/antibiotics10020194. Antibiotics (Basel). 2021. PMID: 33671416 Free PMC article.
-
Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii.Antimicrob Agents Chemother. 2015 Jul;59(7):3920-4. doi: 10.1128/AAC.04986-14. Epub 2015 Apr 20. Antimicrob Agents Chemother. 2015. PMID: 25896698 Free PMC article.
-
Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis.Chemotherapy. 2013;59(5):325-9. doi: 10.1159/000356755. Epub 2014 Feb 13. Chemotherapy. 2013. PMID: 24525528
-
Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.Expert Rev Anti Infect Ther. 2015 Jun;13(6):769-77. doi: 10.1586/14787210.2015.1032254. Epub 2015 Apr 12. Expert Rev Anti Infect Ther. 2015. PMID: 25865094 Review.
-
Efficacy of φkm18p phage therapy in a murine model of extensively drug-resistant Acinetobacter baumannii infection.Infect Drug Resist. 2018 Nov 15;11:2301-2310. doi: 10.2147/IDR.S179701. eCollection 2018. Infect Drug Resist. 2018. PMID: 30532563 Free PMC article. Review.
Cited by
-
Virulence Characteristics and Emerging Therapies for Biofilm-Forming Acinetobacter baumannii: A Review.Biology (Basel). 2022 Sep 12;11(9):1343. doi: 10.3390/biology11091343. Biology (Basel). 2022. PMID: 36138822 Free PMC article. Review.
-
Immune Response Resetting in Ongoing Sepsis.J Immunol. 2019 Sep 1;203(5):1298-1312. doi: 10.4049/jimmunol.1900104. Epub 2019 Jul 29. J Immunol. 2019. PMID: 31358659 Free PMC article.
-
Efficacy of dual carbapenem treatment in a murine sepsis model of infection due to carbapenemase-producing Acinetobacter baumannii.J Antimicrob Chemother. 2021 Feb 11;76(3):680-683. doi: 10.1093/jac/dkaa487. J Antimicrob Chemother. 2021. PMID: 33227138 Free PMC article.
-
Alterations of Gut Microbiome and Metabolite Profiling in Mice Infected by Schistosoma japonicum.Front Immunol. 2020 Oct 8;11:569727. doi: 10.3389/fimmu.2020.569727. eCollection 2020. Front Immunol. 2020. PMID: 33162984 Free PMC article.
-
Repurposing of the Tamoxifen Metabolites to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli.Antibiotics (Basel). 2021 Mar 22;10(3):336. doi: 10.3390/antibiotics10030336. Antibiotics (Basel). 2021. PMID: 33810067 Free PMC article.
References
-
- Fernández-Cuenca F, Tomás-Carmona M, Caballero-Moyano F, Bou G, Martínez-Martínez L, Vila J, Pachón J, Cisneros JM, Rodríguez-Baño J, Pascual A, Grupo del Proyecto GEIH-REIPI-Ab 2010. 2013. In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: multicenter national study GEIH-REIPI-Ab 2010. Enferm Infecc Microbiol Clin 31:4–9. - PubMed
-
- Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, Gallego-Lara SL, Madrazo-Osuna J. 2003. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36:1111–1118. doi:10.1086/374337. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases